SARCOIDOSIS AND THE NERVOUS SYSTEM


Dave Haight* and Carol McConnell**

You are Visitor Number to this page last updated November 20, 1998.

 


* David Haight was at the time of the initial version (July 10, 1996) a 3rd year medical student at BGSM on his first clinical rotation, Neurology. He was inspired to look-up some information after taking care of an unusual patient with CNS Sarcoid.
Carol McConnell was also a 3rd year medical student, but was on her last clinical rotation of the year while I was her attending and we diagnosed sarcoid in another patient. She revised and added to the document.
Both are students of the class of 1998 at the Bowman Gray School of Medicine

OUTLINE


INTRODUCTION
EPIDEMIOLOGY
ETIOLOGY/PATHOLOGY
CLINICAL PRESENTATION
DIAGNOSIS
THERAPY
REFERENCES

INTRODUCTION {Back to Outline}

Sarcoidosis a systemic disease of young adults with an unknown etiology, inconsistent manifestations, and an unpredictable course.

EPIDEMIOLOGY {Back to Outline}

Sarcoidosis affects both sexes, all races, and all ages throughout the world. In the United States and Europe, the prevalence is between 10 and 40 per 100,000. This disease tends to appear in young adults between the ages of twenty and forty. US blacks are affected by this disease ten to seventeen times as often as whites are. In Europe, however, mostly whites are affected (1). Women seem to be affected slightly more often than men. Nonsmokers are affected more than smokers. There are more cases of sarcoidosis found during the winter and early spring (2).

ETIOLOGY/PATHOLOGY {Back to Outline}

Studies are not definitive, but both genetic and environmental factors seem to be involved in development of the disease. Monozygotic twins are more likely to both be affected than dizygotes in some cases which suggests a genetic etiology. No link to HLA antigens have been proven. Reports of non-related individuals living together contracting the disease suggest an environmental etiology (1).

Evidence indicates that sarcoidosis is caused by an inherited or acquired exaggerated cellular immune response to a limited class of antigens or self-antigens (1). The characteristic lesion of sarcoidosis is the noncaseating granuloma which is formed by the accumulation of T lymphocytes and mononuclear phagocytes (1). Pathologically, sarcoidosis resembles tuberculosis and other granulomatous diseases (3). Sarcoidosis causes damage by the derangement of normal tissue architecture through space occupation rather than by the release of any mediators or exotoxins. (1) Lesions can be found in any organ. Lungs are involved in over 90% of patients. Thoracic lymph nodes are involved in 75-90%. Other organs are involved as follows: skin 25%, eyes 25%, upper respiratory tract 20%, joints 15-20%, marrow 15-40%, liver 60-90%, heart 5%, bone 5%, nervous system 5%, kidney 1-2% (1).

CLINICAL PRESENTATION {Back to Outline}

The presenting symptoms and signs of sarcoidosis are quite variable. In ten to twenty percent of cases, this disorder is discovered incidentally in asymptomatic patients on a routine chest x-ray. Typically, sarcoidosis patients present with constitutional symptoms such as fatigue, malaise, fever, anorexia, and weight loss. Twenty to forty percent of patients have an acute or subacute presentation with symptoms developing over weeks. The vast majority (40-70%) of patients have an insidious, chronic presentation which develops over months. Signs of the disease include: lymphadenopathy, pulmonary infiltrates, ocular lesions, and skin lesions. Because the lung is the most commonly affected organ, most patients have some respiratory problems including chest pain, cough and dyspnea. Ninety percent of patients have an abnormal chest x-ray during their course. Fifty percent of patients have permanent lung abnormalities.

Approximately five percent of patients with systemic sarcoidosis have the variant which affects the nervous system termed "neurosarcoidosis" (4-6). However, only half of these patients have neurologic symptoms (6). Neurosarcoidosis can affect practically any part of the central or peripheral nervous system (7). However, it has a predilection for the base of the brain (3). When intracranial, it tends to involve the cranial nerves, meninges, optic chiasm, hypothalamus, and pituitary (4,6,8). It can also involve the parenchyma of the brain and ependymal lining, and rarely present as a mass lesion worrisome for a tumor (9). Signs of intracranial involvement include: headache, lethargy, polydipsia, polyuria, hydrocephalus, seizures, decreased visual acuity, papilledema, and optic atrophy (3).

Of the cranial nerves, the facial (seventh) is the most commonly affected and usually presents as a transient unilateral lower motor neuron deficit (3). The triad of chronic uveitits, parotitis, and facial nerve involvement is fairly common and has been termed "Uveoparotid Syndrome" (3). The optic nerve is the second most commonly involved cranial nerve, occurring in 5% of the cases of neurosarcoidosis. Symptoms of optic nerve involvement include blurred vision, field defects, blindness, and pupillary abnormalities. An exam of the optic disk may reveal edema of the optic disk, optic neuritis or optic atrophy. The glossopharyngeal and vagus nerves are the next most commonly involved cranial nerves and their involvement can cause hoarseness or palate dysfunction. With involvement of the eighth cranial nerve, patients have changes in their hearing.

When the meninges are involved patients present with an aseptic or tuberculous meningitis which may be recurrent (3).

Seizures are present in 5-25% of patients with neurosarcoidosis. Jacksonian, psychomotor, and myoclonic variants have been documented with grand mal predominating. Unfortunately, presence of seizures portends a bad outcome. Those with seizures are more likely to have a progressive, relapsing course than others with neurosarcoidosis. In one study the five patients who dies of the disease rather than of another cause all had seizures. Seventy five per cent of those with seizures failed to respond well to steroids.

Psychological manifestations of neurosarcoidosis may include apathy, lack of judgment or memory loss. Agitation, hallucination, and other symptoms can also occur.

Sarcoidosis can also invade the spinal cord and cause a myelopathy(10-14). Also, peripheral neuropathy of one or more nerves occurs in 6 to 18% of patients with neurosarcoidosis (6,15). It can affect motor or sensory nerves and be detected by EMG studies (7).

DIAGNOSIS {Back to Outline}

Diagnosis is based mainly on the clinical findings described above. Lab abnormalities in systemic sarcoidosis include lymphocytosis, mild eosinophilia, increased erythrocyte sedimentation rate, hyperglobulinemia, and rarely hypercalcemia (7). Increased serum angiotensin converting enzyme has been shown to be 56-86% sensitive (16,17). Chest x-ray is the number one diagnostic tool. Gallium lung scan is more sensitive than chest x-ray and it, along with bronchioalveolar lavage, is often used to support the diagnosis (16,18). Definitive diagnosis requires clinical and radiological signs plus histological confirmation of noncaseating lesions. Biopsy of lymph nodes, lung, bone, uvea, skin, muscle, conjunctiva, and lip may be performed.

For neurosarcoidosis in particular, cranial CT with contrast is a useful test which shows granulomas as "high attenuating homogenous enhancing lesions". MRI is very sensitive and is better for detection of ventricular enlargement and white matter lesions (3). Cerebrospinal fluid findings are variable and may include an increased protein, low glucose, mild pleocytosis of lymphocytes (10-200 WBC/mm3), and an elevated angiotensin converting enzyme level (3,7). A Kveim-Siltzbach skin test which is similar to a TB test can be done and is 80% specific with a false positive rate of 5%. This test is not widely available (3). Electroencephalogram and cerebral angiography have no added benefit over the aforementioned less invasive tests (7).

Conditions which should be included in the differential diagnosis are: leprosy, tuberculosis, cryptococcus, syphilis, epidemic parotitis, and multiple sclerosis (3).

TREATMENT {Back to Outline}

In general, the prognosis of sarcoidosis is good. Although about 10% of patients die as a direct effect of the disease, in half of the patients with sarcoidosis, the disease resolves spontaneously. However, it is unclear in which patients this will occur. Most patients suffer no significant sequelae. The recommended treatment of neurosarcoidosis is prednisone at an initial dose of 40 to 80 mg per day in divided doses. This is tapered off slowly over a period of weeks (3). Often symptoms worsen when the steroids are tapered. If this occurs or if the patient is unresponsive to treatment, the dose may need to be increased. An immunosuppressive drug such as cyclosporin may be added so that the steroid dose can be lowered (3,19,20). A last option is treatment with 1 to 3000 rads of radiation fractionated over several days to weeks. This regimen has been used with favorable response, but gives only temporary relief (21). After radiation, steroids usually need to be resumed, sometimes at lower dosages. Surgery is only recommended if there is hydrocephalus or some other form of pressure or mass effect in the cranium (7). Unfortunately, one third of patients relapse after treatment and high dose steroids or other measures are required (22).

 

 

 

 

 

REFERENCES {Back to Outline}

1. Crystal RG. Sarcoidosis, in Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci

AS, Kasper DL (eds). Harrison’s Principles of Internal Medicine, 13th ed. New

York. McGraw-Hill, 1994. pp. 1679-1684.

2. Bardinas F, Morera J, Fite E, Plasencia A. Seasonal clustering of sarcoidosis. Lancet

1989;2:455-6.

3. Adams RD, Victor M, Ropper AH (eds). Principles of Neurology, 6th ed. New York.

McGraw-Hill, 1997. pp. 720-722.

4. Delaney P. Neurologic manifestations in sarcoidosis: Review of the literature, with a

report of 23 cases. Ann Intern Med 87:336, 1977.

5. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around

the world. Am J Med 57:847, 1974.

6. Stern BJ, Krumholz A, John SC, et al. Sarcoidosis and its neurological manifestations.

Arch Neurol 42:909, 1985.

7. Scott TF. Neurosarcoidosis: Progress and clinical aspects. Neurol 43(1):8-12, 1993.

8. Cariski AT. Isolated CNS sarcoidosis. JAMA 1981;245:62-63.

9. Spencer N, Ross G, Helm G, Madison J, Urich H. Aqueductal obstruction in

sarcoidosis. Clin Neuropathol 1989;8:158-161.

10. Day AL, Sypert GW. Spinal cord sarcoidosis. Ann Neurol 1977;1:79-85.

11. Sauter MK, Panitch HS, Kristt DA. Myelopathic neurosarcoidosis: diagnostic value

of enhanced MRI. Neurology 1991; 41:150-151.

12. Terunuma H, Konno H, Iizuka H, Yamamoto T, Iwasaki Y, Youshimoto T.

Sarcoidosis presenting as progressive myelopathy. Clin Neuropathol 1988;7:77-80.

13. Vighetto A, Fischer G, Collet P, Bady B, Trillet M. Intramedullary sarcoidosis of the

cervical spinal cord. J Neurol Neurosurg Psychiatry 1985;48:477-479.

14. Clifton AG, Stevens JM, Kapoor R, Rudge P. Spinal cord sarcoidosis with

intramedullary cyst formation. Br J Radiol 1990;63:805-808.

15. Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta

Med Scand 1986;73:283-290.

16. Israel H, Gushue G, Park C. Assessment of gallium-67 scanning in pulmonary and

extrapulmonary sarcoidosis. Ann NY Acad Sci 1986;465:455-462.

17. Shultz T, Miller WC, Bedrossian CW. Clinical application of measurement of

angiotensin-converting enzyme level. JAMA 1979;242:439-441.

18. Nosal A, Schleissner LA, Mishkin FS, Lieberman J. Angiotensin-I-converting enzyme

and gallium scan in non-invasive evaluation of sarcoidosis. Ann Intern Med

1979;90:328-331.

19. Kavannaugh AF, Andrew SL, Cooper B, Lawrence EC, Huston DP. Cyclosporin

therapy of central nervous system sarcoidosis. Am J Med 1987;82:387.

20. Chapelon C, Ziza JM, Piette JC, et al. Neurosarcoidosis: signs, course, and treatment

in 35 confirmed cases. Medicine 1990;69:261-276.

21. Gelwan MJ, Kellen RI, Burde RM, Kupersmith MJ. Sarcoidosis of the anterior visual

pathway: successes and failures. J Neurol Neurosurg Psychiatry 1988;51:1473-

1480.

22. Luke RA, Stern BJ, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical

course. Neurology 1987;37: 461-463.

 

Return to: G&T Homepage '99
Go to: Neurology Page

Copyright © 1996-1998 MEDMAN